GLP-1 drugs with rectal cancer therapy study
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests whether adding a GLP-1 receptor agonist (a diabetes/weight-loss medication) to standard rectal cancer treatment improves outcomes for patients with rectal cancer who are overweight or obese. It is for those with mismatch repair proficient (pMMR) rectal cancer that hasn't spread and requires a specific MRI finding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that is mismatch repair proficient (pMMR, meaning your cancer cells can fix DNA errors normally).
- You have a body mass index (BMI) of 25 or higher (considered overweight or obese).
- Your cancer has not spread to other parts of the body (no metastases).
- Your cancer is seen on MRI as more than T2, with positive lymph nodes, threatened surgical margin, or blood vessel invasion (EMVI+).
- You have not had chemotherapy or radiation therapy for rectal cancer before.
- You are able to undergo MRI scans.
- You have not had any weight-loss treatment (medication or surgery) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding the immunotherapy drug tislelizumab to standard total neoadjuvant treatment (chemotherapy and radiation before surgery) can improve outcomes for people with locally advanced rectal cancer. The goal is to see if the combination helps shrink the tumor more than standard treatment alone.
This trial tests a combination of focused radiation therapy given quickly, along with chemotherapy, targeted drugs, and immunotherapy before surgery for locally advanced rectal cancer. The goal is to shrink the tumor and improve survival chances by treating the cancer aggressively before an operation.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial tests a combination of radiation, chemotherapy (CAPOX), and immunotherapy (iparomlimab and tuvonralimab) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs, chemotherapy, and bevacizumab given before surgery for locally advanced rectal cancer. It aims to see if this approach can shrink tumors and improve outcomes.
This trial tests adding immunotherapy to standard radiation and chemotherapy for patients with locally advanced rectal cancer. The goal is to see if a personalized approach improves outcomes while sparing more normal tissue.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.